Skip to content

US · EW · MEDICAL - DEVICES

Edwards Lifesciences Corporation (EW) intrinsic value and stock valuation

$101.85as of 2026-11-21 · Mkt cap 51.23B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Edwards Lifesciences Corporation DCF and intrinsic value

InvestorsCraft values EW with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from EW’s statements →

Edwards Lifesciences Corporation Graham Number

Graham Number: $27.02d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Devices Irvine, CA 92614 edwards.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$6.07B+6.7% 5y CAGRd
20112025
Net income
$1.07B+5.4% 5y CAGRd
20112025
Free cash flow
$1.34B+15.6% 5y CAGRd
20112025
Total equity
$10.3B+17.7% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$6.07B$5.44B$5.01B$5.38B$5.23B
Operating income$1.64B$1.38B$1.43B$1.7B$1.61B
Net income$1.07B$4.17B$1.4B$1.52B$1.5B
EPSd$1.83M$6.97M$2.3M$2.44M$2.38M
Operating cash flow$1.6B$542.3M$895.8M$1.22B$1.73B
Capital expenditure-$-260.2M-$-252.4M-$-266.3M-$-264.8M-$-329.8M
Free cash flow$1.34B$289.9M$629.5M$953.4M$1.4B
Total assets$13.7B$13.1B$9.36B$8.29B$8.5B
Total debt$705.4M$700M$685.1M$691.3M$690.3M
Net debt-$-2.23B-$-2.35B-$-447.2M-$-77.7M-$-172.5M
Total equity$10.3B$10.1B$6.72B$5.81B$5.84B
Cash and short-term investments$4.23B$3.98B$1.63B$1.22B$1.47B
Income statement
20252024202320222021
Revenue$6.07B$5.44B$5.01B$5.38B$5.23B
Cost of revenue$1.33B$1.12B$1.04B$1.17B$1.23B
Gross profit$4.74B$4.32B$3.97B$4.22B$4.01B
Research and development expenses$1.08B$1.05B$962.9M$945.2M$903.1M
Selling, general and administrative expenses$2.09B$1.79B$1.58B$1.57B$1.49B
Other expenses-$-59.9M$101.1M$0.00$0.00$0.00
Operating expenses$3.1B$2.94B$2.55B$2.51B$2.4B
Cost and expenses$4.43B$4.06B$3.58B$3.68B$3.62B
Interest income$148.4M$120.3M$67.2M$35.5M$17.4M
Interest expense$0.00$19.8M$17.6M$26.2M$24.8M
Depreciation and amortization$156.6M$155.2M$144.9M$166.8M$163.3M
Ebitda$1.43B$1.72B$1.53B$1.96B$1.89B
Operating income$1.64B$1.38B$1.43B$1.7B$1.61B
Total other income/expenses, net-$-363.3M$169.4M-$-54.9M$65M$91.6M
Income before tax$1.27B$1.55B$1.37B$1.77B$1.7B
Income tax expense$216.9M$152.1M$152.4M$245.5M$198.9M
Net income$1.07B$4.17B$1.4B$1.52B$1.5B
Weighted average shares outstanding$584.8M$597.7M$606.7M$619M$623.3M
Weighted average diluted shares outstanding$585.8M$599.3M$609.4M$624.2M$631.2M
Balance sheet
20252024202320222021
Cash and short-term investments$4.23B$3.98B$1.63B$1.22B$1.47B
Net receivables$912.1M$727.4M$828.1M$699.1M$664.9M
Inventory$1.13B$1.09B$903.5M$875.5M$726.7M
Total current assets$6.74B$6.29B$4.04B$3.1B$3.18B
Property, plant and equipment, net$1.91B$1.78B$1.68B$1.73B$1.64B
Goodwill and intangible assets$2.9B$2.95B$1.54B$1.45B$1.49B
Long-term investments$773.9M$307.9M$583.9M$1.24B$1.83B
Total non-current assets$6.96B$6.77B$5.33B$5.2B$5.32B
Total assets$13.7B$13.1B$9.36B$8.29B$8.5B
Accounts payable$227.5M$197.4M$186.6M$201.9M$204.5M
Short-term debt$24.5M$23.4M$22.9M$25.5M$25.5M
Deferred revenue$27.2M$53.7M$0.00$0.00$0.00
Total current liabilities$1.81B$1.51B$1.2B$1.02B$1.03B
Long-term debt$680.9M$676.6M$662.2M$665.8M$664.8M
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$1.55B$1.49B$1.45B$1.46B$1.63B
Capital lease obligations$82.6M$102.3M$88.1M$95M$94.6M
Total liabilities$3.36B$2.99B$2.64B$2.49B$2.67B
Common stock$658.7M$654.8M$650.5M$646.3M$642M
Retained earnings$14.2B$13.2B$8.99B$7.59B$6.07B
Accumulated other comprehensive income (loss)-$-238.3M-$-244.5M-$-242.8M-$-254.9M-$-157.7M
Total equity$10.3B$10.1B$6.72B$5.81B$5.84B
Total investments$2.06B$1.24B$1.08B$1.69B$2.44B
Total debt$705.4M$700M$685.1M$691.3M$690.3M
Net debt-$-2.23B-$-2.35B-$-447.2M-$-77.7M-$-172.5M
Cash flow statement
20252024202320222021
Net income$1.07B$4.17B$1.4B$1.52B$1.5B
Depreciation and amortization$156.6M$155.2M$144.9M$139.6M$134.8M
Stock-based compensation$158.1M$162.3M$139.4M$126.8M$109.3M
Change in working capital$154.6M-$-259.3M-$-526.3M-$-421.4M$145.3M
Accounts receivable-$-23M$121.2M-$-141.2M-$-84.1M-$-112.4M
Inventory$50.7M-$-256.1M-$-289M-$-213.4M$19M
Accounts payable$395.1M$89.5M$146M-$-21.4M$195.2M
Net cash provided by operating activities$1.6B$542.3M$895.8M$1.22B$1.73B
Investments in property, plant and equipment-$-260.2M-$-282.4M-$-266.3M-$-264.8M-$-329.8M
Acquisitions, net$0.00-$-1.06B-$-95.2M$0.00$329.8M
Net cash used for investing activities-$-712.9M$2.31B$173.8M$252.3M-$-1.72B
Common stock issued$174.1M$0.00$0.00$0.00$0.00
Common stock repurchased-$-893.4M-$-1.16B-$-879.6M-$-1.73B-$-512.8M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-956.8M-$-983M-$-711M-$-1.58B-$-356.3M
Net change in cash-$-119.3M$1.91B$375.4M-$-94.8M-$-332.8M
Cash at end of period$2.94B$3.06B$1.15B$772.6M$867.4M
Operating cash flow$1.6B$542.3M$895.8M$1.22B$1.73B
Capital expenditure-$-260.2M-$-252.4M-$-266.3M-$-264.8M-$-329.8M
Free cash flow$1.34B$289.9M$629.5M$953.4M$1.4B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Edwards Lifesciences Corporation

        Edwards Lifesciences Corporation is a global medical technology firm specializing in sophisticated products and technologies for structural heart conditions, alongside critical care and surgical patient monitoring. With operations spanning the United States, Europe, Japan, and various international territories, the company offers a comprehensive suite of solutions. Their structural heart disease portfolio encompasses transcatheter heart valve replacement systems designed for minimally invasive procedures, as well as transcatheter repair and replacement options specifically targeting mitral and tricuspid valve pathologies, exemplified by their PASCAL and Cardioband systems. Additionally, they provide advanced surgical structural heart solutions, including the INSPIRIS aortic surgical valve, the KONECT RESILIA pre-assembled aortic tissue valved conduit for complex valve, root, and ascending aorta replacements, and the HARPOON Beating Heart Mitral Valve Repair System for patients suffering from degenerative mitral regurgitation. In the realm of critical care, Edwards supplies advanced hemodynamic monitoring systems that assess patients' cardiac function and fluid status in both surgical and intensive care environments. This offering also features the Acumen Hypotension Prediction Index software, which provides early alerts to clinicians regarding potential dangerously low blood pressure. The company distributes its products to healthcare providers through a combination of its proprietary sales force and independent distributor networks. Founded in 1958, Edwards Lifesciences Corporation maintains its headquarters in Irvine, California.

        CEO
        Bernard J. Zovighian
        Employees
        16K
        Beta
        0.85

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Edwards Lifesciences Corporation (EW)?

        Edwards Lifesciences Corporation (EW) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is EW undervalued?

        EW trades at a price of $101.85 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.